-
Genor Biopharma to Acquire EOC Pharma Group in a Merger Deal, Eyeing Commercialization Synergies
•
Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma Group (China) Co., Ltd. As part of the agreement, Genor Biopharma will acquire EOC Pharma through a share exchange, resulting in a reverse takeover. The company will change its name to “Edding Genor Group Holdings…
-
Genor Biopharma Strikes Licensing Deal with TRC 2004 for Global Rights to GB261 Outside Greater China
•
China-based Genor Biopharma Co., Ltd (HKG: 6998) has entered into a significant licensing and equity agreement with US-based TRC 2004, Inc., bestowing upon TRC 2004 the exclusive rights to develop, manufacture, and commercialize Genor’s innovative drug candidate, GB261, in all global territories excluding Greater China. This strategic partnership is set…
-
Genor Biopharma’s Lerociclib Accepted for Review by China’s NMPA for Breast Cancer Treatment
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the market filing for its cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor, lerociclib (GB491), has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of hormone receptor (HR) positive, human epidermal…
-
Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication
•
Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA) has accepted its filing for another indication approval of lerociclib (GB491), a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. The new indication seeks to utilize lerociclib in combination with letrozole for patients with hormone receptor-positive…
-
Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration (NMPA) has declined its New Drug Application (NDA) for geptanolimab, a programmed-death 1 (PD-1) inhibitor, for the treatment of recurrent/refractory peripheral T-cell lymphoma (PTCL). The drug, which was under development to treat a range of…
-
Genor Biopharma Initiates First Patient Dosing for GB263T in China
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a Phase I/II clinical study for its pipeline candidate GB263T in advanced non-small cell lung cancer (NSCLC) and other solid tumors in China. The drug was first administered in a first-in-human trial in Australia in May…
-
Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies
•
China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor’s biologic antibody development platform with Abogen’s mRNA technology platform. Collaboration DetailsThe partnership combines…
